Authors
Latest:
The Future of Periodontal TreatmentAdvancements in periodontal disease could make way for expansions in the dental space and other medical fields.
Latest:
Remote Reliance: The Rise of Oncology Home CareWhile hurdles remain, home healthcare could deliver better patient-centered cancer care—providing improved outcomes, enhanced quality of life, and reduced strain on resources.
Latest:
Biopharma Needs a Health System Strategy to Secure Optimal Market AccessIn today’s pharmaceutical market access landscape, payers are not the sole decision-makers in utilization management development.
Latest:
Patient-Centricity in Biopharma: Selling Health Versus PillsDevesh Verma and Rebecca Lorenzo outline some the challenges and potential solutions to building a patient-centric culture
Latest:
Why Every Pharma Executive Should Be Watching the Regeneron Kickback CaseThe Regeneron litigation highlights that donations routed through independent entities are not immune from challenge, especially if the government believes they are effectively covering a patient’s co-pay for a specific product.
Latest:
IDMP in a COVID ContextLise Stevens explores what difference the ISO IDMP (Identification of Medicinal Products) data standards would have made in a COVID-19 context — in applications ranging from pharmacovigilance adverse event reporting and electronic prescribing to falsified medicines control.
Latest:
Why the Pandemic is Rewriting the Biopharma Rule BookChanges necessitated by COVID will drive unprecedented transformation of industry.
Latest:
China’s 2022 NRDL OutlookThe 2022 National Reimbursement Drug List will see more pressures for new inclusions on the one hand, and more certainties for renewals on the other. At the same time, the process is becoming more interactive and transparent.
Latest:
Fair Market Value vs. Current Market LeverageHow pharmaceutical manufacturers should consider their Fair Market Value cost assessment compared to their negotiation leverage when contracting for distribution services
Latest:
A Brand Game-Changer? TikTok and Pharma MarketingIt’s time for pharma brands to recognize the potential of TikTok as a promotional platform and develop a strategy to not only stand out but make an impact.
Latest:
Climbing Health Care Costs Result in Elevated Employer VigilanceSoaring healthcare costs show little sign of slowing in 2024, with concerns growing about the affordability of medications and medical services.
Latest:
Are We Forgetting to Develop Vaccines for Diseases other than COVID?It's time to apply the same COVID-19 urgency to other devastating diseases, such as Alzheimer’s, write Andrea Pfeifer and William Mobley.
Latest:
3 ASCO Insights for Pharma CommunicatorsThe world’s largest cancer research meeting, the American Society of Clinical Oncology (ASCO) Annual Meeting, recently convened in person in Chicago after two years of being held virtually. Sara Baker and Kristine Austria Fan of Marina Maher Communications provide their takeaways from the meeting.
Latest:
Building Pharma and Lab Spaces in New Jersey 2021–Adapting to Changing NeedsNJ can regain leadership in pharma by offering modern lab spaces for biotech and other lab-based growth companies.
Latest:
Key Factors Attributing to a Successful Product LaunchWhat the c-suite should consider in today’s marketplace.
Latest:
Pharma’s Business Case for RWE: Tapping the Full Value From These InsightsHow drugmakers can better harness real-world evidence to drive their clinical and commercial objectives, while also providing greater clarity for healthcare providers and improved access to therapy for the patients they serve.
Latest:
A Culture of Quality: The Catalyst to Accelerate InnovationWhy enabling a shared culture of quality across an organization is key to maintaining pharma’s recent pace of innovation wins—while inspiring new levels of confidence.
Latest:
The Real Cost of State Drug Importation Programs? Patient SafetyImporting drugs from Canada may increase the risk of US citizens being exposed to unsafe medicines.
Latest:
From Potential to Value: Carving a Slice of the CGT ‘PIE'The importance of pre-approval information exchange (PIE) with payers and other strategic considerations to help navigate today’s market access challenges and regulatory requirements in bringing promising cell and gene therapies to the market.
Latest:
Three Keys to Ireland’s Resilient Pharma IndustryRecent growth in pharma makes Ireland an ideal candidate for expansion opportunities.
Latest:
Making America Great Again through the Vital Contributions of the U.S. Biopharmaceutical SectorThe biopharmaceutical sector is underpinned by a unique ecosystem that combines public funding for basic research, university-led translational science, technology transfers, venture capital funding, partnerships with larger companies, and a relatively transparent and responsive regulatory system.
Latest:
Recent Federal Circuit Developments in Patent LicensingUnderstanding of recent legal developments can help companies avoid infringement.
Latest:
With Project Optimus, Success Favors the PreparedOncology drug developers must start asking questions in preparation of FDA’s dose optimization initiative.
Latest:
Rethinking Market Access in CEE: Time to Bust the MythsChallenging six misconceptions that have characterized product strategies in Central and Eastern European markets.
